Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by sherritt2018giron Mar 09, 2021 10:04am
139 Views
Post# 32751620

The aggressive behavior on this board should and must stop

The aggressive behavior on this board should and must stop Aggressive behavior rarely happens without a reason. Please try to be civilized and relevant at all times.

I believe MEDIVOLVE has the potential to be an excellent short term play over the next month, as its $25-$35 million in projected revenues for Q1 clearly illustrate that this company is severely undervalued compared to others in the same field . This, combined with the good chunk of money for the Investor Relations marketing campaign, gives Medivolve a good chance at drumming up support from investors to positively impact share price in the next 4-6 weeks.
 
At the same time as I am optimistic, I will caution that Medivolve has a lot of work to do to impress on shareholders that it can deliver both in terms of creating value for investors by increasing it's beaten down share price AND in creating a strong and smart plan to pivot the company into future viability... No small task, but one that I believe is possible. I actually think they might be an attractive company for acquisition, depending on how the next few months go.
 
Bottom line for me is that I believe there is a strong chance that I personally will be able to make money off of MEDIVOLVE. I believe they have a very good chance at doubling or tripling their share price in the coming weeks.



<< Previous
Bullboard Posts
Next >>